BR112018010806A2 - compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer - Google Patents

compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer

Info

Publication number
BR112018010806A2
BR112018010806A2 BR112018010806A BR112018010806A BR112018010806A2 BR 112018010806 A2 BR112018010806 A2 BR 112018010806A2 BR 112018010806 A BR112018010806 A BR 112018010806A BR 112018010806 A BR112018010806 A BR 112018010806A BR 112018010806 A2 BR112018010806 A2 BR 112018010806A2
Authority
BR
Brazil
Prior art keywords
hydrogen
methoxy
cancer treatment
thiadiazole compounds
trifluoromethoxy
Prior art date
Application number
BR112018010806A
Other languages
English (en)
Portuguese (pt)
Inventor
Wilhelmus Maria Nissink Johannes
David Charles Mark
Raymond Verschoyle Finlay Maurice
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of BR112018010806A2 publication Critical patent/BR112018010806A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018010806A 2015-11-30 2016-11-30 compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer BR112018010806A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260789P 2015-11-30 2015-11-30
PCT/EP2016/079250 WO2017093299A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
BR112018010806A2 true BR112018010806A2 (pt) 2018-11-27

Family

ID=57485461

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010806A BR112018010806A2 (pt) 2015-11-30 2016-11-30 compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer

Country Status (23)

Country Link
US (3) US10323028B2 (https=)
EP (1) EP3383873B1 (https=)
JP (1) JP6999550B2 (https=)
KR (1) KR20180083942A (https=)
CN (1) CN108349966B (https=)
AR (1) AR106874A1 (https=)
AU (1) AU2016363718B2 (https=)
BR (1) BR112018010806A2 (https=)
CA (1) CA3005495C (https=)
CL (1) CL2018001407A1 (https=)
CO (1) CO2018006928A2 (https=)
EA (1) EA201891241A1 (https=)
ES (1) ES2914333T3 (https=)
IL (1) IL259510A (https=)
MX (1) MX2018006532A (https=)
NI (1) NI201800064A (https=)
PH (1) PH12018501131A1 (https=)
RU (1) RU2018123714A (https=)
SG (1) SG11201803810XA (https=)
SV (1) SV2018005702A (https=)
TN (1) TN2018000127A1 (https=)
TW (1) TW201733587A (https=)
WO (1) WO2017093299A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
ES2903182T3 (es) * 2017-06-13 2022-03-31 Medshine Discovery Inc Compuesto como inhibidor GLS1
AU2019363115B2 (en) 2018-10-16 2021-12-09 Medshine Discovery Inc. Thiadiazole derivative and uses thereof as a GLS1 inhibitor
WO2025196446A1 (en) * 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
ES2761866T3 (es) * 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
BR112015010955A2 (pt) * 2012-11-16 2017-07-11 Calithera Biosciences Inc inibidores de glutaminase heterocíclica
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
CA2934700A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
EP3116872A4 (en) * 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
CN108349966A (zh) 2018-07-31
JP2018535986A (ja) 2018-12-06
SG11201803810XA (en) 2018-06-28
TW201733587A (zh) 2017-10-01
US10323028B2 (en) 2019-06-18
JP6999550B2 (ja) 2022-02-10
TN2018000127A1 (en) 2019-10-04
KR20180083942A (ko) 2018-07-23
CL2018001407A1 (es) 2018-10-12
AU2016363718A1 (en) 2018-07-12
WO2017093299A1 (en) 2017-06-08
AR106874A1 (es) 2018-02-28
SV2018005702A (es) 2018-11-27
RU2018123714A (ru) 2020-01-09
EP3383873B1 (en) 2022-03-09
MX2018006532A (es) 2019-05-15
NI201800064A (es) 2018-10-18
IL259510A (en) 2018-07-31
EP3383873A1 (en) 2018-10-10
CA3005495C (en) 2023-12-12
CN108349966B (zh) 2022-02-15
EA201891241A1 (ru) 2019-01-31
US11753405B2 (en) 2023-09-12
US10981904B2 (en) 2021-04-20
CO2018006928A2 (es) 2018-10-10
AU2016363718B2 (en) 2019-11-14
CA3005495A1 (en) 2017-06-08
US20170152255A1 (en) 2017-06-01
US20190389853A1 (en) 2019-12-26
PH12018501131A1 (en) 2019-01-21
US20210246131A1 (en) 2021-08-12
ES2914333T3 (es) 2022-06-09

Similar Documents

Publication Publication Date Title
BR112018010806A2 (pt) compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer
CR20200376A (es) Inhibidores de cd73
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
MX389450B (es) Compuesto novedoso de pirimidina condensada o sal del mismo.
JOP20180113B1 (ar) مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
MY197626A (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
BR112018014794A2 (pt) pirimidinas substituídas com arila para uso em infecção pelo vírus influenza
BR112018010812A2 (pt) compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer
BR112018008330A2 (pt) compostos 1,3,4-tiadiazol e seu uso no tratamento de câncer
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MX394245B (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
CO2022000270A2 (es) Inhibidores de enzimas
PH12021550374A1 (en) Small molecule menin inhibitors
BR112017021589A2 (pt) métodos para o tratamento de transtornos cardiovasculares
MX389613B (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
BR112018070526A2 (pt) tratamento do carcinoma de células renais com lenvatinibe e everolimo
BR112018016554A2 (pt) composto de uréia, método de preparação deste e uso médico deste
BR112019002576A2 (pt) composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
PL428024A1 (pl) Sulfonowana pochodna polistyrenu do zastosowania w leczeniu i/lub profilaktyce infekcji wywołanej przez kociego herpeswirusa
BR112016004511A8 (pt) Composto, composto ou uma forma do mesmo, uso de um composto ou forma do mesmo, e composição farmacêutica para uso no tratamento de um câncer mediado por bmi-1
EA202090672A2 (ru) ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]